Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer.

18 Mar 2016

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.

17 Mar 2016

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.

17 Mar 2016

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment.

17 Mar 2016

New 10-minute test can quickly assess specific food compounds in human urine

Researchers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, have developed a method that can quickly evaluate specific food compounds in human urine. They say their method could one day replace unreliable food logs used in population studies examining the effects of diet on cancer and will also help scientists accurately identify the most beneficial anticancer foods.

17 Mar 2016

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

16 Mar 2016

New research finds racial disparities in screening for lung cancer

New research from the Yale School of Public Health reveals that differences in smoking habits between African Americans and whites may lead to a disparity in screening for lung cancer.

16 Mar 2016

Genetic study in Sub-Saharan Africa hopes to provide new information about etiology of prostate cancer

Dana-Farber Cancer Institute researchers are leading a multicenter genetic study of prostate cancer in Sub-Saharan Africa to try to find new information about the genetic etiology of prostate cancer

16 Mar 2016

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

In global clinical trials, patients with advanced metastatic lung cancer who were treated with a targeted immunotherapy drug lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published today in the journal The Lancet.

15 Mar 2016

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients.

15 Mar 2016

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing.

15 Mar 2016

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

15 Mar 2016

Preoperative lapatinib plus trastuzumab elicits response in HER2-positive breast cancer

Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.

14 Mar 2016

Researchers exploring ways to prevent radiation-induced cancer risk in astronauts

NASA limits an astronaut's radiation exposures to doses that keep their added risk of fatal cancer below 3 percent. Unfortunately, that ceiling restricts the time an astronaut may spend in space, which in turn restricts the ability to perform longer missions, say a mission to Mars.

14 Mar 2016

Use of contralateral prophylactic mastectomy tripled from 2002 to 2012 despite no survival benefit

The use of contralateral prophylactic mastectomy (CPM), the surgical removal of a breast unaffected by cancer as part of the course of treatment for breast cancer, has more than tripled from 2002 to 2012 despite evidence suggesting no survival benefit over breast conservation, according to a new study from Brigham and Women's Hospital published in Annals of Surgery on March 11, 2016.

14 Mar 2016

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.

13 Mar 2016

Research uncovers biological differences between male, female breast cancers

Male breast cancer (Male BC) has important biological differences that distinguish it from female breast cancer, but to date these have been little studied and Male BC patients have been excluded from many clinical trials in breast cancer.

11 Mar 2016

Negative cancer clinical trials have long-term impact on research

Cancer clinical trials with negative results don't make an immediate splash in the scientific literature, but they do have a long-term impact on cancer research, according to a new study by SWOG, the federally funded international clinical trials network.

11 Mar 2016

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

The creation of a network of centres of reference and adopting measures that promote research and access to treatments are two key aspects for improving the prognosis of patients with soft tissue sarcoma (STS), an uncommon type of cancer that originates in the tissues that connect, support and surround other body structures, such as muscles, fat, blood vessels, nerves, tendons and lining of the joints.

11 Mar 2016

Conserved gene can act to inhibit lung cancer development, study finds

Scientists believe that "conserved" genes — those found in life forms that range from bacteria to plants, insects and humans — perform vital biological functions across species. And limited research on one of those genes, Nitrilase 1 (Nit1), suggested it acts to inhibit cancer development.

11 Mar 2016

Oncology News and Research

Further Reading

Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Vascular events in CML may not be linked to TKI therapy

Real-life data show feasibility of imatinib discontinuation in CML

New 10-minute test can quickly assess specific food compounds in human urine

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

New research finds racial disparities in screening for lung cancer

Genetic study in Sub-Saharan Africa hopes to provide new information about etiology of prostate cancer

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Anticancer drug restores hearing in neurofibromatosis patients

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Preoperative lapatinib plus trastuzumab elicits response in HER2-positive breast cancer

Researchers exploring ways to prevent radiation-induced cancer risk in astronauts

Use of contralateral prophylactic mastectomy tripled from 2002 to 2012 despite no survival benefit

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

Research uncovers biological differences between male, female breast cancers

Negative cancer clinical trials have long-term impact on research

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

Conserved gene can act to inhibit lung cancer development, study finds

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News